Synthetic Lethal Therapy for KRAS Mutant Non-Small-Cell Lung Carcinoma With Nanoparticle-Mediated CDK4 siRNA Delivery

Molecular Therapy - United States
doi 10.1038/mt.2014.18
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner

Molecular Pharmaceutics
Drug DiscoveryMolecular MedicinePharmaceutical Science
2012English

Atorvastatin Overcomes Gefitinib Resistance in KRAS Mutant Human Non-Small Cell Lung Carcinoma Cells

Cell Death and Disease
Molecular NeuroscienceImmunologyCell BiologyCancer ResearchCellularMedicine
2013English

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours

PLoS ONE
Multidisciplinary
2016English

KRAS Mutation, KRAS–LCS6 Polymorphism, and Non-Small Cell Lung Cancer

Lung Cancer
Cancer ResearchOncologyRespiratory MedicinePulmonary
2010English

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Recent Developments in Nanoparticle-Based siRNA Delivery for Cancer Therapy

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2013English

P2.03-14 PKCi-PAK1 Pathway Modulates Sensitivity to Therapy in EGFR, KRAS Mutant and Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Antibody-Mediated Delivery of Anti-Kras-siRNA in Vivo Overcomes Therapy Resistance in Colon Cancer

Clinical Cancer Research
Cancer ResearchOncology
2015English

Mutational Profiling of KRAS and Its Association With Non-Small Cell Lung Carcinoma in Indian Kashmiri Population

Canadian Journal of Biotechnology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy